Tissue Engineered Nigrostriatal Pathway as an Anatomically-Inspired Test-Bed for Evaluating Axonal Pathophysiology
Objective: We previously developed the first micro-tissue engineered nigrostriatal pathway encased in a tubular hydrogel with 3D structure, multicellular composition, and architecture of long axonal…A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…Longitudinal CSF-profile and brain pathology mirrors clinical course of LRRK2-Related Parkinson’s Disease
Objective: Do clinical cognitive profiles and CSF characterisitcs of Abeta1_42, total-tau, phospho-tau and alpha-synuclein during lifetime correspond to histopathological findings post-mortem in LRKK2-associated Parkinson’s disease…Baicalein incorporated nanoliposome disaggregates alpha-synuclein fibrils
Objective: The aim of this study is to evaluate the depolymerization effect of baicalein on mature fibrils of alpha-synuclein. Background: The aggregation and oligomerization of…A Lewy body disease of widely confirmed Lewy bodies in the cerebral cortexes including the occipital lobe without pathological changes in the hippocampal CA2/3 region
Objective: We present Lewy body disease (LBD) showing unique neuropathological findings which are widely recognized Lewy bodies (LBs) in the cerebral cortexes including the occipital…DNAJC13 in Parkinson’s disease; characterization of the p.N855S knock-in mouse model
Objective: To study the effects of DNAJC13 p.Asn855Ser mutant gene dysfunction in a physiological context, and to help define molecular mechanisms for disease, using a…A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies
Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…The effect of ATP13A2/PARK9 levels on a-syn spreading in mice brains
Objective: The purpose of this study is to analyze the effect of ATP13A2/PARK9-mediated a-syn secretion on a-syn spreading in mice. Background: Recent studies with cell…A genome wide pleiotropic approach to identify the genetic architecture of multiple system atrophy and its interaction with Parkinson’s disease
Objective: The aim of this study is to provide new insights into the genetic architecture of multiple system atrophy (MSA) and investigate shared molecular genetic…Neuromodulatory potentials of revasterol and Carpogon capitatus Roxb on the rat brain: Novel approach for Parkinson’s diseases
Objective: The aim of the current study is to explore the synergistic effects of revasterol and Carpogon capitatus extract Roxb in rotenone induced rat model…
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 60
- Next Page »